诊断时不确定性肺结节与高级别骨肉瘤患者生存期的关联如何
该回顾性研究纳入2008至2016年484例初诊高级别骨肉瘤或骨梭形细胞肉瘤患者,按诊断时胸部CT分为无转移、不确定性肺结节(IPN,<1 cm)和转移三组。控制混杂因素后,IPN与更差的总生存和无转移生存相关,74%的IPN在5.3个月中位时间证实为真转移。作者认为诊断时IPN应纳入治疗决策讨论,其管理方式需进一步研究。
要点
- 诊断时16%(68/431)患者存在IPN,14%(61/431)存在肺转移。
- IPN组总生存劣于无转移组,2年总生存65% vs 83%。
- 74%(50/68)IPN在中位5.3个月证实为真转移。
核心结论
- 诊断时存在IPN与较无转移患者更差的生存相关。
- 高级别骨肉瘤和骨梭形细胞肉瘤患者诊断时发现的IPN应与患者讨论并纳入治疗决策考虑。
- IPN应如何处理尚需进一步研究阐明。
研究设计与样本
- 2008年至2016年从机构数据库回顾性识别484例初诊骨肉瘤或骨梭形细胞肉瘤患者。
- 排除标准包括:在其他机构治疗(6%,27/484)、新辅助化疗并发症相关死亡(1%,3/484)、最终病理分级1或2级(4%,21/484)、缺乏可复习的分期胸部CT(0.4%,2/484)。
- 所有分期胸部CT异常者经资深放射科顾问医师复核,分为无转移(70%,302/431)、IPN(16%,68/431)、转移(14%,61/431)三组比较。
- 随机抽取部分CT由资深放射科住院医师复核,两位阅片者间一致性很好(κ=0.88)。
主要发现
- 控制局部控制策略、肿瘤大小和化疗诱导坏死等混杂变量后,IPN与更差总生存相关(HR 1.9 [95%CI 1.3至2.8];p=0.001),与更高转移发生率相关(HR 3.6 [95%CI 2.5至5.2];p<0.001)。
- 无转移组、IPN组、转移组的2年总生存分别为83% [95%CI 78至87]、65% [95%CI 52至75]、45% [95%CI 32至57](p=0.001)。
- 74%(50/68)IPN患者在中位5.3个月证实为真转移灶,其中86%(43/50)在诊断后2年内疾病进展。
- IPN患者多变量分析中,非手术治疗与更差结局相关(HR 3.6 [95%CI 1.5至8.3];p=0.003),继发性肉瘤与更差结局相关(HR 3.4 [95%CI 1.1至10.0];p=0.03)。
- 单变量分析中结节矿化与更好总生存相关(87% [95%CI 39至98] vs 57% [95%CI 43至69];p=0.008),但因无法在多变量分析中控制其他因素,矿化与生存的关系无法确定;未能发现其他结节影像学特征与生存的关联。
关键数值与推荐
- IPN定义为诊断时小于1 cm的结节;肺转移定义为实质结节10 mm或更大。
- 无转移组、IPN组、转移组分别占70%(302/431)、16%(68/431)、14%(61/431)。
- 三组在年龄、性别、亚型、病理性骨折、肿瘤部位、化疗诱导坏死方面无差异,在局部控制策略和肿瘤大小方面存在差异,转移组中更大肿瘤尺寸和接受非手术治疗者比例更大。
- 三组随访丢失无差异:无转移组2%(6/302)、IPN组0%、转移组2%(1/61)在诊断后1年失访但未知死亡。
- IPN组中随机抽取部分胸部CT由资深放射科住院医师复核(κ=0.62)。
临床怎么用
- 作者认为诊断时IPN应与患者讨论并纳入治疗决策考虑。
- 作者指出IPN应如何处理尚需进一步研究阐明。
- 原文未据此给出其他推荐。
局限性
- 矿化与生存的关系因无法在多变量分析中控制其他因素而无法确定。
- IPN应如何处理尚需进一步研究阐明。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Pulmonary metastases are a poor prognostic factor in patients with osteosarcoma; however, the clinical significance of subcentimeter lung nodules and whether they represent a tumor is not fully known. Because the clinician is faced with decisions regarding biopsy, resection, or observation of lung nodules and the potential impact they have on decisions about resection of the primary tumor, this remains an area of uncertainty in patient treatment. Surgical management of the primary tumor is tailored to prognosis, and it is unclear how aggressively patients with indeterminate pulmonary nodules (IPNs), defined as nodules smaller than 1 cm at presentation, should be treated. There is a clear need to better understand the clinical importance of these nodules. QUESTIONS/PURPOSES: (1) What percentage of patients with high-grade osteosarcoma and spindle cell sarcoma of bone have IPNs at diagnosis? (2) Are IPNs at diagnosis associated with worse metastasis-free and overall survival? (3) Are there any clinical or radiologic factors associated with worse overall survival in patients with IPN? METHODS: Between 2008 and 2016, 484 patients with a first presentation of osteosarcoma or spindle cell sarcoma of bone were retrospectively identified from an institutional database. Patients with the following were excluded: treatment at another institution (6%, 27 of 484), death related to complications of neoadjuvant chemotherapy (1%, 3 of 484), Grade 1 or 2 on final pathology (4%, 21 of 484) and lack of staging chest CT available for review (0.4%, 2 of 484). All patients with abnormalities on their staging chest CT underwent imaging re-review by a senior radiology consultant and were divided into three groups for comparison: no metastases (70%, 302 of 431), IPN (16%, 68 of 431), and metastases (14%, 61 of 431) at the time of diagnosis. A random subset of CT scans was reviewed by a senior radiology registrar and there was very good agreement between the two reviewers (κ = 0.88). Demographic and oncologic variables as well as treatment details and clinical course were gleaned from a longitudinally maintained institutional database. The three groups did not differ with regard to age, gender, subtype, presence of pathological fracture, tumor site, or chemotherapy-induced necrosis. They differed according to local control strategy and tumor size, with a larger proportion of patients in the metastases group presenting with larger tumor size and undergoing nonoperative treatment. There was no differential loss to follow-up among the three groups. Two percent (6 of 302) of patients with no metastases, no patients with IPN, and 2% (1 of 61) of patients with metastases were lost to follow-up at 1 year postdiagnosis but were not known to have died. Individual treatment decisions were determined as part of a multidisciplinary conference, but in general, patients without obvious metastases received (neo)adjuvant chemotherapy and surgical resection for local control. Patients in the no metastases and IPN groups did not differ in local control strategy. For patients in the IPN group, staging CT images were inspected for IPN characteristics including number, distribution, size, location, presence of mineralization, and shape. Subsequent chest CT images were examined by the same radiologist to reevaluate known nodules for interval change in size and to identify the presence of new nodules. A random subset of chest CT scans were re-reviewed by a senior radiology resident (κ = 0.62). The association of demographic and oncologic variables with metastasis-free and overall survival was first explored using the Kaplan-Meier method (log-rank test) in univariable analyses. All variables that were statistically significant (p < 0.05) in univariable analyses were entered into Cox regression multivariable analyses. RESULTS: Following re-review of staging chest CTs, IPNs were found in 16% (68 of 431) of patients, while an additional 14% (61 of 431) of patients had lung metastases (parenchymal nodules 10 mm or larger). After controlling for potential confounding variables like local control strategy, tumor size, and chemotherapy-induced necrosis, we found that the presence of an IPN was associated with worse overall survival and a higher incidence of metastases (hazard ratio 1.9 [95% CI 1.3 to 2.8]; p = 0.001 and HR 3.6 [95% CI 2.5 to 5.2]; p < 0.001, respectively). Two-year overall survival for patients with no metastases, IPN, or metastases was 83% [95% CI 78 to 87], 65% [95% CI 52 to 75] and 45% [95% CI 32 to 57], respectively (p = 0.001). In 74% (50 of 68) of patients with IPNs, it became apparent that they were true metastatic lesions at a median of 5.3 months. Eighty-six percent (43 of 50) of these patients had disease progression by 2 years after diagnosis. In multivariable analysis, local control strategy and tumor subtype correlated with overall survival for patients with IPNs. Patients who were treated nonoperatively and who had a secondary sarcoma had worse outcomes (HR 3.6 [95% CI 1.5 to 8.3]; p = 0.003 and HR 3.4 [95% CI 1.1 to 10.0]; p = 0.03). The presence of nodule mineralization was associated with improved overall survival in the univariable analysis (87% [95% CI 39 to 98] versus 57% [95% CI 43 to 69]; p = 0.008), however, because we could not control for other factors in a multivariable analysis, the relationship between mineralization and survival could not be determined. We were unable to detect an association between any other nodule radiologic features and survival. CONCLUSION: The findings show that the presence of IPNs at diagnosis is associated with poorer survival of affected patients compared with those with normal staging chest CTs. IPNs noted at presentation in patients with high-grade osteosarcoma and spindle cell sarcoma of bone should be discussed with the patient and be considered when making treatment decisions. Further work is required to elucidate how the nodules should be managed. LEVEL OF EVIDENCE: Level III, prognostic study.
引用
- Tsoi KM, Lowe M, Tsuda Y, et al. How Are Indeterminate Pulmonary Nodules at Diagnosis Associated with Survival in Patients with High-Grade Osteosarcoma? Clin Orthop Relat Res. 2021. PMID: 32956141. doi:10.1097/CORR.0000000000001491
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。